InvestorsHub Logo
Followers 5
Posts 359
Boards Moderated 0
Alias Born 01/10/2019

Re: docz21321312 post# 42271

Wednesday, 06/12/2019 5:04:55 PM

Wednesday, June 12, 2019 5:04:55 PM

Post# of 232962
Yes, that's nonsense, or at least, let's say, quite optimistic, given that CYDY doesn't get any love from investors for even a completed Phase 3 study in combo and a completed investigational Phase 3 mono trial.

Galectin, which is about to start a Phase 3 trial in NASH, has a current market cap of about $180M.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News